A promising new medicine against heart disease fails unexpectedly
An experimental heart disease drug called pelacarsen failed a crucial clinical trial despite successfully cutting levels of lipoprotein(a) in the blood by seventy-eight percent. Medical professionals held high expectations that the treatment would serve as a major advance in preventing strokes, heart attacks, and cardiovascular deaths. Instead, the medication showed zero benefit and made no difference in preventing cardiovascular complications or saving patients' lives. Following the disappointing results, Novartis is largely abandoning the experimental drug, which analysts previously considered a potential blockbuster treatment.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ The experimental heart drug pelacarsen failed to reduce cardiovascular deaths, heart attacks, or strokes.
- ✓ Pelacarsen successfully cut lipoprotein(a) levels by 78 percent.
- ✓ Novartis is largely abandoning the experimental drug following the surprising failure in a key study.
- ✓ The drug's zero benefit outcome casts a shadow over Amgen and Lilly programs.
What changed
Novartis is largely abandoning the experimental heart disease drug pelacarsen following its unexpected failure in a key clinical study.
Live updates
-
Heart Drug Pelacarsen Fails Major Clinical Trial
An experimental heart disease drug called pelacarsen failed a crucial clinical trial despite successfully cutting levels of lipoprotein(a) in the blood by seventy-eight percent. Medical professionals held high expectations that the treatment would serve as a major advance in preventing strokes, heart attacks, and cardiovascular deaths. Instead, the medication showed zero benefit and made no difference in preventing cardiovascular complications or saving patients' lives. Following the disappointing results, Novartis is largely abandoning the experimental drug, which analysts previously considered a potential blockbuster treatment.
Why it matters
Elevated lipoprotein(a) particles are a common inherited risk factor linked to heart attacks and strokes, leaving cardiologists searching for effective preventive treatments. The unexpected failure of pelacarsen to translate biomarker reduction into clinical survival benefits deals a severe blow to these prevention efforts. And this negative outcome casts a shadow over similar drug development programs led by Amgen and Lilly.
What is confirmed
- The experimental heart drug pelacarsen failed to reduce cardiovascular deaths, heart attacks, or strokes.
- Pelacarsen successfully cut lipoprotein(a) levels by 78 percent.
- Novartis is largely abandoning the experimental drug following the surprising failure in a key study.
- The drug's zero benefit outcome casts a shadow over Amgen and Lilly programs.
What to watch next
- Decisions by Amgen and Lilly regarding their respective Lp(a) drug programs following the pelacarsen trial failure.
- Detailed data presentations from researchers regarding the pelacarsen clinical trial.
confidence 100%Sources used for this update (16)
- www.wuot.org — Death toll hits 29 after Russian strike on Ukrainian aid site, with 48 still missing
- NPR — A promising new medicine against heart disease fails unexpectedly
- CNN — Pelacarsen, a promising drug for an inherited heart risk, flops, stunning doctors
- The New York Times — How Cardiologists’ High Hopes for Two Drugs Were Dashed
- NBC News — The ‘slam dunk’ that wasn’t: Promising cholesterol drug fails to prevent heart attacks or stroke
- Fierce Biotech — Novartis’ Lp(a) drug shows zero benefit, casting shadow over Amgen and Lilly programs
- newenglandnewspress.com — A promising new drug for heart disease unexpectedly fails
- www.emjreviews.com — Promising Heart Drug Disappoints After Failing to Reduce Deaths
- www.hppr.org — A promising new medicine against heart disease fails unexpectedly
- rocketnews.com — A promising new medicine against heart disease fails ...
- www.yahoo.com — ‘American Pickers’ star Frank Fritz’s multimillion-dollar estate fight heads to trial
- malaysia.news.yahoo.com — 'Godzilla' child star's next role recast with sister after death at 18
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community